IPCALAB.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 12:00):

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India...

Stats
Dagens volum	384 574
Gjennomsnittsvolum	564 065
Markedsverdi	338.44B
EPS	INR0 ( 2024-02-13 )
Neste inntjeningsdato	( INR5.60 ) 2024-05-27
Last Dividend	INR4.00 ( 2022-11-22 )
Next Dividend	INR0 ( N/A )
P/E	60.09
ATR14	INR2.19 (0.16%)

Volum Korrelasjon

Lang: 0.55 (weak)

Kort: -0.70 (moderate negative)

Signal:(62.796) Neutral

Ipca Laboratories Limited Korrelasjon

10 Mest positive korrelasjoner
ALLCARGO.NS	0.878
RAJVIR.NS	0.838
AJRINFRA.NS	0.808
KHAITANLTD.NS	0.801

10 Mest negative korrelasjoner
FOCUS.NS	-0.833
AGI.NS	-0.82
BANCOINDIA.NS	-0.816
KOVAI.NS	-0.812
MAYURUNIQ.NS	-0.81
MEGH.NS	-0.804
HILTON.NS	-0.804
FINCABLES.NS	-0.802
BECTORFOOD.NS	-0.802
SUPERHOUSE.NS	-0.802

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

Ipca Laboratories Limited Korrelasjon - Valuta/Råvare

-0.26
( neutral )

-0.45
( neutral )

-0.64
( weak negative )

-0.27
( neutral )

0.04
( neutral )

0.25
( neutral )

Ipca Laboratories Limited Økonomi

Annual	2022
Omsetning:	INR62.44B
Bruttogevinst:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
Omsetning:	INR62.44B
Bruttogevinst:	INR39.38B (63.06 %)
EPS:	INR18.58

FY	2022
Omsetning:	INR57.66B
Bruttogevinst:	INR36.60B (63.48 %)
EPS:	INR34.85

FY	2021
Omsetning:	INR53.41B
Bruttogevinst:	INR35.39B (66.27 %)
EPS:	INR45.01

Financial Reports:

No articles found.

Ipca Laboratories Limited Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR0 (N/A)	INR4.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

Ipca Laboratories Limited Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 3.59 - low (19.38%) | Divividend Growth Potential Score: 1.866 - No dividend expected

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR0.150	1999-11-24
Last Dividend	INR4.00	2022-11-22
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	40	--
Total Paid Out	INR32.15	--
Avg. Dividend % Per Year	0.20%	--
Score	1.8	--
Div. Sustainability Score	3.59
Div.Growth Potential Score	1.866
Div. Directional Score	2.73	--

Next Divdend (Est)
(2024-05-06)

INR0 Estimate 0.00 %

Dividend Stability

0.08 Very Bad

Dividend Score

1.80

Pay Frequency

Annually

Yearly Payout

Year	Amount	Yield
1999	INR0	0.00%
2000	INR0	0.00%
2001	INR0	0.00%
2002	INR0	0.00%
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0.500	0.14%
2019	INR1.500	0.37%
2020	INR6.50	1.14%
2021	INR4.00	0.37%
2022	INR4.00	0.37%
2023	INR0	0.00%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
PLASTIBLEN.NS	Dividend Junior	2023-06-23	Annually	18	1.26%
JKTYRE.NS	Dividend Junior	2023-07-27	Annually	17	0.91%
DIAMONDYD.NS	Dividend Junior	2023-07-27	Annually	7	0.06%
360ONE.NS	Dividend Knight	2023-07-28	Semi-Annually	6	2.85%
SOMANYCERA.NS	Dividend Junior	2023-08-18	Annually	23	0.39%
MOIL.NS	Dividend Knight	2023-09-08	Semi-Annually	14	2.38%
HDFCBANK.NS	Dividend Junior	2023-05-16	Annually	28	0.58%
BHANDARI.NS	Dividend Junior	2023-09-22	Annually	8	0.18%
RAJRATAN.NS	Dividend Junior	2023-07-27	Annually	4	0.12%
KIRLOSIND.NS	Dividend Junior	2023-08-03	Annually	17	0.72%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.0785	1.500	8.43	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.126	1.500	9.71	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	7.15	1.000	8.46	8.46	[3 - 30]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
freeCashFlowPerShareTTM	25.91	2.00	10.00	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.655	1.000	2.42	2.42	[0.2 - 0.8]
operatingProfitMarginTTM	0.127	1.000	9.47	9.47	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				3.59

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	60.13	1.000	4.03	0	[1 - 100]
returnOnEquityTTM	0.126	2.50	9.81	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	25.91	2.00	1.364	10.00	[0 - 30]
dividendYielPercentageTTM	0.150	1.500	6.26	0	[0 - 0.4]
operatingCashFlowPerShareTTM	25.91	2.00	1.364	2.73	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-1.288	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0915	1.000	-0.213	0	[0.1 - 0.5]
Total Score				1.866

Ipca Laboratories Limited

Ipca Laboratories Limited manufactures and markets pharmaceutical formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India. It offers APIs in therapeutic areas of anti-hypertensive, anti-malarial, diuretic, DMARD, and anthelmintic. The company provides generic and branded formulations in the therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, cardiology, dermatology, diabetology, gastroenterology, haematology, neurology, ophthalmology, rheumatology, and urology, as well as respiratory, psychiatry, probiotics, orthopedics, oral anti diabetes drug, nutraceuticals, NSAIDs, neuropathic pain, malaria, infectious diseases, immunosuppressant, hepatoprotectives, helminthics, fever, and emollients/protectives. It exports its products to approximately 100 countries worldwide. The company was incorporated in 1949 and is based in Mumbai, India.